Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Archives of Gynecology and Obstetrics
Erschienen in: Archives of Gynecology and Obstetrics 2/2016

01.02.2016 | Review

An overview of the development and application of the sonographic scoring system: differentiation of malignant from benign ovarian tumors

verfasst von: Z. H. Jiang, K. T. Li, J. W. Tian, M. Ren

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Ultrasonography is routinely used for the examination of ovarian tumors regarding preoperative diagnosis and postoperative therapeutic evaluation. However, its sensitivity and specificity in determining benign from malignant tumors should be further improved. In this study, we review the methods of sonographic scoring system for differentiating benign from malignant ovarian tumors, and its development and application.

Methods

We searched the Medline, EBSCO and China National Knowledge Infrastructure from inception to April 2015, we also used the Google Scholar search engine to obtain studies.

Results

The ultrasonic scoring system has important clinical value in the preoperative diagnosis of ovarian neoplasm, the sensitivity, specificity and accuracy are significantly higher than using conventional ultrasonography by various of ultrasonic techniques, including two-dimensional sonographic imaging, color Doppler imaging, power Doppler ultrasound, real-time three-dimensional ultrasound and contrast-enhanced ultrasonography.

Conclusions

The sonographic scoring system can significantly improve the sensitivity, specificity and accuracy of ultrasonic diagnosis in ovarian tumors, and provides a semi-quantitative method for determining the nature of ovarian masses, guidance of the surgical treatment and evaluation of prognosis.
Literatur
1.
Moore RG, MacLaughlan S, Bast RC Jr (2010) Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 116(2):240–245PubMedPubMedCentralCrossRef
2.
Schwartz PE, Taylor KJ (1995) Is early detection of ovarian cancer possible? Ann Med 27(5):519–528PubMedCrossRef
3.
Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, Jiang SW (2009) HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 9(6):555–566PubMedPubMedCentralCrossRef
4.
Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB (1998) CA 125: the past and the future. Int J Biol Markers 13(4):179–187PubMed
5.
Benjapibal M, Neungton C (2007) Pre-operative prediction of serum CA125 level in women with ovarian masses. J Med Assoc Thai 90(10):1986–1991PubMed
6.
Wilbaux M, Hénin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, Tod M, You B (2014) Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients. Br J Cancer 110(6):1517–1524PubMedPubMedCentralCrossRef
7.
Bian J, Li B, Kou XJ, Liu TZ, Ming L (2013) Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer. Asian Pac J Cancer Prev 14(11):6241–6243PubMedCrossRef
8.
Robati M, Ghaderi A, Mehraban M, Shafizad A, Nasrolahi H, Mohammadianpanah M (2013) Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts. Arch Gynecol Obstet 288(4):859–865PubMedCrossRef
9.
Wu CM, Li XL, Li L, Yin LL, Li Q (2014) Combined detection of tumor makers in the diagnosis of ovarian tumors. Int J Lab Med 35(6):724–725
10.
Sevin BU, Greening SE, Nadji M (1979) Fine needle aspiration cytology in gynecologic oncology. I. Clinical aspects. Acta Cytol 23(4):277–281PubMed
11.
Sevin BU, Nadji M, Greening SE, Ng AB, Nordqvist SR, Girtanner RE, Averette HE (1980) Fine-needle-aspiration cytology in gynecologic oncology: “early detection of occult persistent or recurrent cancer after radiation therapy”. Gynecol Oncol 9(3):351–360PubMedCrossRef
12.
Flint A, Terhart K, Murad TM, Taylor PT (1982) Confirmation of metastases by fine needle aspiration biopsy in patients with gynecologic malignancies. Gynecol Oncol 14(3):382–391PubMedCrossRef
13.
McDonald TW, Morley GW, Choo YC, Shields JJ, Cordoba RB, Naylor B (1983) Fine needle aspiration of para-aortic and pelvic lymph nodes showing lymphangiographic abnormalities. Obstet Gynecol 61(3):383–388PubMed
14.
Fortier KJ, Clarke-Pearson DL, Creasman WT, Johnston WW (1985) Fine-needle aspiration in gynecology: evaluation of extrapelvic lesions in patients with gynecologic malignancy. Obstet Gynecol 65(1):67–72PubMed
15.
Moriarty AT, Glant MD, Stehman FB (1986) The role of fine needle aspiration cytology in the management of gynecologic malignancies. Acta Cytol 30(1):59–64PubMed
16.
Nash JD, Burke TW, Woodward JE, Hall KL, Weiser EB, Heller PB (1988) Diagnosis of recurrent gynecologic malignancy with fine-needle aspiration cytology. Obstet Gynecol 71(3 Pt 1):333–337PubMed
17.
Crosby JH, Bryan AB, Gallup DG, Talledo OE (1989) Fine-needle aspiration of inguinal lymph nodes in gynecologic practice. Obstet Gynecol 73(2):281–284PubMed
18.
Wojcik EM, Selvaggi SM, Johnson SC, Martier SS, Ager JW (1992) Factors influencing fine-needle aspiration cytology in the management of recurrent gynecologic malignancies. Gynecol Oncol 46(3):281–286PubMedCrossRef
19.
Mehdi G, Maheshwari V, Afzal S, Ansari HA, Ansari M (2010) Image-guided fine-needle aspiration cytology of ovarian tumors: An assessment of diagnostic efficacy. J Cytol 27(3):91–95PubMedPubMedCentralCrossRef
20.
Spencer JA (2005) A multidisciplinary approach to ovarian cancer at diagnosis. Br J Radiol 78(2):94–102CrossRef
21.
Forstner R (2007) Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol 17(12):3223–3235PubMedCrossRef
22.
Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ (2000) Staging of advanced ovarian cancer: comparison of imaging modalities–report from the Radiological Diagnostic Oncology Group. Radiology 215(3):761–767PubMedCrossRef
23.
Pannu HK, Horton KM, Fishman EK (2003) Thin section dual-phase of peritoneal metastases in gynecologic cancers. J Comput Assist Tomogr 27(3):333–340PubMedCrossRef
24.
Shiels RA, Peel KR, MacDonald HN, Thorogood J, Robinson PJ (1985) A prospective trial of computed tomography in the staging of ovarian malignancy. Br J Obstet Gynaecol 92(4):407–412PubMedCrossRef
25.
Pectasides D, Kayianni H, Facou A, Bobotas N, Barbounis V, Zis J, Athanassiou A (1991) Correlation of abdominal computed tomography scanning and second-look operation findings in ovarian cancer patients. Am J Clin Oncol 14(6):457–462PubMedCrossRef
26.
Calkins AR, Stehman FB, Wass JL, Smirz LR, Ellis JH (1987) Pitfalls in interpretation of computed tomography prior to second-look laparotomy in patients with ovarian cancer. Br J Radiol 60(718):975–979PubMedCrossRef
27.
Alt CD, Brocker KA, Eichbaum M, Sohn C, Arnegger FU, Kauczor HU, Hallscheidt P (2011) Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 2. Strahlenther Onkol 187(11):705–714PubMedCrossRef
28.
Manegold-Brauer G, Bellin AK, Tercanli S, Lapaire O, Heinzelmann-Schwarz V (2014) The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging. Arch Gynecol Obstet 289(3):491–492PubMedCrossRef
29.
Manganaro L, Michienzi S, Vinci V, Falzarano R, Saldari M, Granato T, Viggiani V, Frati L, Anastasi E (2013) Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep 30(5):2481–2487PubMed
30.
Alvarez Moreno E, Jimenez de la Peña M, Cano Alonso R (2012) Role of new functional MRI techniques in the diagnosis, staging, and followup of gynecological cancer: comparison with PET-CT. Radiol Res Pract 2012:219546PubMedPubMedCentral
31.
Xian JF, Du HR, Wang XY, Yan F, Zhang ZY, Hao H, Zhao B, Tong YJ, Zhang Y, Han DM (2014) Feasibility and value of quantitative dynamic contrast enhancement MR imaging in the evaluation of sinonasal tumors. Chin Med J (Engl) 127(12):2259–2264
32.
Takemori M, Nishimura R, Hasegawa K (2002) Clinical evaluation of MRI in the diagnosis of borderline ovarian tumors. Acta Obstet Gynecol Scand 81(2):157–161PubMedCrossRef
33.
Thomassin-Naggara I, Bazot M, Daraï E, Callard P, Thomassin J, Cuenod CA (2008) Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology 248(1):148–159PubMedCrossRef
34.
Kurjak A, Shalan H, Kupesic S, Predanic M, Zalud I, Breyer B, Jukic S (1993) Transvaginal color Doppler sonography in the assessment of pelvic tumor vascularity. Ultrasound Obstet Gynecol 3(2):137–154PubMedCrossRef
35.
Caruso A, Caforio L, Testa AC, Ciampelli M, Panici PB, Mancuso S (1996) Transvaginal color Doppler ultrasonography in the presurgical characterization of adnexal masses. Gynecol Oncol 63(2):184–191PubMedCrossRef
36.
Schelling M, Braun M, Kuhn W, Bogner G, Gruber R, Gnirs J, Schneider KT, Ulm K, Rutke S, Staudach A (2000) Combined transvaginal B-mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecol Oncol 77(1):78–86PubMedCrossRef
37.
Alcázar JL, Mercé LT, García Manero M (2005) Three—dimensional power Doppler vascular sampling: A new method for predicting ovarian cancer in vascularized complex adnexal masses. J Ultrasound Med 24(5):689–696PubMed
38.
Meire HB, Farrant P, Guha T (1978) Distinction of benign from malignant ovarian cysts by ultrasound. Br J Obstet Gynaecol 85(12):893–899PubMedCrossRef
39.
Finkler NJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC (1988) Comparison of serum CA125, clinical impression and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 72(4):659–664PubMed
40.
Granberg S, Norström A, Wikland M (1990) Tumors in the lower pelvis as imaged by vaginal sonograghy. Gynecol Oncol 37(2):224–229PubMedCrossRef
41.
Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB (1991) Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 78(1):70–76PubMed
42.
DePriest PD, Shenson D, Fried A, Hunter JE, Andrews SJ, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR (1993) A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 51(1):7–11PubMedCrossRef
43.
Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G (1994) Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 170(1):81–85PubMedCrossRef
44.
Ferrazzi E, Zanetta G, Dordoni D, Berlanda N, Mezzopane R, Lissoni AA (1997) Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study. Ultrasound Obstet Gynecol 10(3):192–197PubMedCrossRef
45.
Mera E, Weber G, Bahlmann F, Kiesslich R (1998) A new sonomorphologic scoring system (Mainz Score) for the assessment of ovarian tumors using transvaginal ultrasonography. Part|: A comparison between the scoring-system and the assessment by an experienced sonographer. Uhraschall Med 19(3):99–107
46.
Alcázar JL, Mercé LT, Laparte C, Jurado M, López-García G (2003) A new scoring system to differentiate benign from malignant adnexal masses. Am J Obstet Gynecol 188(3):685–692PubMedCrossRef
47.
Huchon C, Metzger U, Bats AS (2012) Value of three-dimensional contrast-enhanced power Doppler ultrasound for characterizing adnexal masses. J Obstet Gynaecol Res 38(5):832–840PubMedCrossRef
48.
Sun LJ, Wu QQ, Chen Y, Ma YQ, Yao L, Niu HM, Wang L (2010) A study of an ultrasound-based scoring system for preoperative assessment of ovarian tumors and assisting triage for surgical management. Chin J Med Ultrasound (Electronic Edition) 7(4):29–32
49.
Xiang H, Huang R, Cheng JX, Gulinaer S, Hu R, Feng YL, Liu H (2013) Value of three-dimensional contrast-enhanced ultrasound in the diagnosis of small adnexal masses. Ultrasound Med Biol 39(5):761–768PubMedCrossRef
50.
Acs G (2005) Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol 123(Suppl):13–57
51.
Moszynski R, Szubert S, Szpurek D, Michalak S, Krygowska J, Sajdak S (2013) Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors. Arch Gynecol Obstet 288(6):1377–1383PubMedPubMedCentralCrossRef
52.
Karadag B, Kocak M, Kayikcioglu F, Ercan F, Dilbaz B, Kose M, Haberal A (2014) Risk for malignant and borderline ovarian neoplasms following basic preoperative evaluation by ultrasonography, Ca125 level and age. Asian Pac J Cancer Prev 15(19):8489–8493PubMedCrossRef
53.
Wilailak S, Chan KK, Chen CA, Nam JH, Ochiai K, Aw TC, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Charakorn C, Sumpaico WW (2015) Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. J Gynecol Oncol 26(1):46–53PubMedPubMedCentralCrossRef
Metadaten
Titel
An overview of the development and application of the sonographic scoring system: differentiation of malignant from benign ovarian tumors
verfasst von
Z. H. Jiang
K. T. Li
J. W. Tian
M. Ren
Publikationsdatum
01.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 2/2016
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-015-3957-x

Weitere Artikel der Ausgabe 2/2016

Archives of Gynecology and Obstetrics 2/2016 Zur Ausgabe

Review

Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives

Review

Pelvic congestion syndrome: the current state of the literature

Gynecologic Oncology

Clinical presentation, treatment and outcome of vaginal intraepithelial neoplasia

Gynecologic Oncology

Identification of key genes associated with the effect of estrogen on ovarian cancer using microarray analysis

Review

An overview of triple-negative breast cancer

General Gynecology

Development of obstetrical and gynecological journals, 2007 to 2013: a trend analysis

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise